ArticleScientific reports2026
Clinical benefit of palbociclib retreatment after abemaciclib exposure in hormone receptor positive, HER2 negative metastatic breast cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) combined with endocrine therapy are standard first-line treatment for HR + /HER2- metastatic breast cancer (MBC). However, disease progression and treatment-limiting adverse events (AEs) remain major challenges, and the clinical benefit of CDK4/6i retreatment after prior exposure is uncertain. We retrospectively analyzed 78 patients with HR + /HER2 - MBC treated at two institutions (2018-2025) who received at least two CDK4/6i-containing therapies. Patients were classified according to treatment sequence: abemaciclib → abemaciclib (cohort 1), abemaciclib → palbociclib (cohort 2), or palbociclib → abemaciclib (cohort 3). Median time to treatment failure (TTF) of CDK4/6i retrial was 6, 10, and 6 months across the three cohorts, respectively. Cohort 2 showed the most favorable retrial outcomes, with 64.5% of patients achieving a longer TTF on retrial than on initial CDK4/6i therapy. Discontinuation due to AEs was associated with a trend toward longer TTF compared with progression, whereas visceral metastasis was associated with shorter TTF in cohort 2 (hazard ratio 12.03, p = 0.01). CDK4/6i retrial may provide clinically meaningful benefit for selected patients, particularly with palbociclib after abemaciclib exposure or discontinuing initial therapy due to AEs, whole visceral metastasis predicts poorer outcomes with retreatment. These findings support individualized patient selection and warrant prospective validation to optimize sequencing strategies for CDK4/6is.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.